PipelineReview. Business Intellegence Center

All News

6 April 2010

Oregovomab: Quest PharmaTech Discloses Cancer Immunotherapy Development StrategyAntibodies

5 April 2010

AnaptysBio Announces Collaboration with VLST to Generate Novel Antibody TherapeuticsAntibodies

1 April 2010

Symphogen Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the USAntibodies

30 March 2010

Lpath Completes Successful Phase I Study With ASONEP in Cancer Patients and Achieves $2 Million Merck KGaA MilestoneAntibodies

29 March 2010

Erbitux Granted extended Use in Japan for First-Line-Treatment for mCRC-Patients with KRAS wild-type TumorsAntibodies

26 March 2010

ABLYNX SELECTS A NOVEL PRE-CLINICAL DEVELOPMENT CANDIDATE FOR ADMINISTRATION VIA PULMONARY DELIVERYAntibodies

25 March 2010

Biogen Idec and Elan Enroll First Patient in Large, Well-Controlled Head-to-Head Study of Multiple Sclerosis TreatmentsAntibodies

23 March 2010

Pain Therapeutics Announces Encouraging Clinical Data With a New Drug for Skin CancerAntibodies

22 March 2010

MabThera filed with EU Health Authorities for maintenance treatment of previously untreated advanced follicular lymphomaAntibodies

22 March 2010

Zenyaku Kogyo Obtains Exclusive License in Japan to Theraclone’s Influenza Monoclonal Antibody ProgramAntibodies

19 March 2010

Anti-Cancer Agents, Herceptin and XelodaAntibodies

18 March 2010

OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human ProteomeAntibodies

17 March 2010

CytoDyn Begins Full Humanization of CytolinAntibodies

17 March 2010

HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN NON-SMALL CELL LUNG CANCERAntibodies

17 March 2010

Monoclonal antibody BT-061 shows efficacy in the indication psoriasisAntibodies

16 March 2010

Single Short Course of Tolerx’s Otelixizumab Provides Prolonged Preservation of Beta Cell FunctionAntibodies

16 March 2010

4-Antibody Announces a Long-Term Collaboration With Boehringer Ingelheim for Therapeutic AntibodiesAntibodies

16 March 2010

Genentech Submits Supplemental Biologics License Application for ACTEMRA (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid ArthritisAntibodies

15 March 2010

Innate Immune, Inc. Enters into a License and Commercialization Agreement with Cephalon Australia Pty LtdAntibodies

14 March 2010

XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart AttackAntibodies

12 March 2010

XOMA 052 Phase 2 Trial Initiated in Type 1 Diabetes PatientsAntibodies

12 March 2010

Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate CancerAntibodies

11 March 2010

Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung CancerAntibodies

11 March 2010

BioInvent and Human Genome Sciences Announce Collaboration to Co-develop and Commercialize Therapeutic AntibodiesAntibodies

9 March 2010

Successful Development of Broad Spectrum Human Monoclonal Antibodies Against Major Influenza Viruses (H1N1 and H5N1)Antibodies

8 March 2010

Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer PatientsAntibodies

8 March 2010

Roche and Biogen Idec decide to suspend Ocrelizumab treatment – Rheumatoid Arthritis development programme on holdAntibodies

4 March 2010

CSL Behring Receives FDA Approval of Hizentra, First 20 Percent Subcutaneous Immunoglobulin TherapyAntibodies

2 March 2010

FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant PatientsAntibodies

1 March 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodiesAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review
CCR8-Targeted Antibody Immunotherapy Pipeline Review
2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
B7-H3-Targeted Immunotherapy Candidates Pipeline Review
Aflibercept (Eylea) Biosimilars Pipeline Review
CD38-Targeted Antibody & Cell Therapy Pipeline Review
IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review